

Gere Sunder-Plassmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6823505/publications.pdf>

Version: 2024-02-01

191
papers

6,566
citations

70961

41
h-index

76769

74
g-index

194
all docs

194
docs citations

194
times ranked

5890
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. <i>Nature Medicine</i> , 2008, 14, 1088-1096.	15.2	420
2	Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. <i>European Heart Journal</i> , 2007, 28, 1228-1235.	1.0	320
3	High prevalence of hyperhomocysteinemia in critically ill patients. <i>Critical Care Medicine</i> , 2000, 28, 991-995.	0.4	286
4	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>Journal of Medical Genetics</i> , 2017, 54, 288-296.	1.5	262
5	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 36.	1.2	239
6	Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2006, 95, 86-92.	0.7	184
7	Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>PLoS Medicine</i> , 2014, 11, e1001750.	3.9	184
8	Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1323-1329.	3.0	174
9	Predialysis Serum Sodium Level, Dialysate Sodium, and Mortality in Maintenance Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2012, 59, 238-248.	2.1	145
10	Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. <i>British Journal of Haematology</i> , 2001, 113, 357-364.	1.2	135
11	Dialysate Sodium Concentration and the Association with Interdialytic Weight Gain, Hospitalization, and Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 92-100.	2.2	131
12	Anemia and Iron Deficiencies among Long-Term Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 794-797.	3.0	117
13	Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey. <i>Clinical Journal of Pain</i> , 2007, 23, 535-542.	0.8	115
14	Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. <i>Kidney International</i> , 1997, 52, 517-523.	2.6	112
15	Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1106-1116.	3.0	111
16	Significance of Interdialytic Weight Gain versus Chronic Volume Overload: Consensus Opinion. <i>American Journal of Nephrology</i> , 2013, 38, 78-90.	1.4	107
17	HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. <i>Kidney International</i> , 1995, 48, 1967-1971.	2.6	86
18	The effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation in men. <i>Resuscitation</i> , 2004, 60, 253-261.	1.3	80

#	ARTICLE	IF	CITATIONS
19	Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii41-ii50.	0.4	75
20	Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. <i>Kidney International</i> , 1998, 53, 1775-1782.	2.6	74
21	The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 60-69.	2.2	65
22	Prevalence of Uncontrolled Hypertension in Patients With Fabry Disease. <i>American Journal of Hypertension</i> , 2006, 19, 782-787.	1.0	64
23	A prospective study of anaemia and long-term outcomes in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3559-3566.	0.4	64
24	Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease. <i>American Journal of Nephrology</i> , 2009, 29, 353-361.	1.4	63
25	Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. <i>Kidney International</i> , 1999, 55, 1072-1080.	2.6	61
26	Citrate for long-term hemodialysis: Prospective study of 1,009 consecutive high-flux treatments in 59 patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 557-564.	2.1	60
27	C-Reactive Protein and Body Mass Index Independently Predict Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 1148-1154.	2.6	59
28	Effect of MTHFR 1298A>T and MTHFR 677C>T Genotypes on Total Homocysteine, Folate, and Vitamin B12 Plasma Concentrations in Kidney Graft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1918-1925.	3.0	57
29	Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1020-1029.	3.0	56
30	Increased serum activity of interleukin-2 in patients with pre-eclampsia. <i>Journal of Autoimmunity</i> , 1989, 2, 203-205.	3.0	51
31	Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 255-260.	3.0	51
32	Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. <i>Kidney International</i> , 1998, 54, 1637-1651.	2.6	50
33	Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. <i>Kidney International</i> , 2003, 63, 2280-2285.	2.6	46
34	Impairment of Transendothelial Leukocyte Migration by Iron Complexes. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2639-2644.	3.0	46
35	Sodium Setpoint and Sodium Gradient: Influence on Plasma Sodium Change and Weight Gain. <i>American Journal of Nephrology</i> , 2011, 33, 39-48.	1.4	46
36	Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. <i>Kidney International</i> , 2018, 93, 753-760.	2.6	46

#	ARTICLE	IF	CITATIONS
37	Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1193-1200.	2.1	45
38	Simplified citrate anticoagulation for high-flux hemodialysis. <i>American Journal of Kidney Diseases</i> , 2001, 38, 979-987.	2.1	45
39	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 219-228.	0.5	44
40	Percentage of Hypochromic Red Blood Cells is an Independent Risk Factor for Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 2075-2081.	2.6	43
41	Supraclavicular approach to the subclavian/innominate vein for large-bore central venous catheters. <i>American Journal of Kidney Diseases</i> , 1997, 30, 802-808.	2.1	41
42	Cinacalcet Decreases Bone Formation Rate in Hypercalcemic Hyperparathyroidism after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2010, 31, 482-489.	1.4	41
43	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. <i>Scientific Reports</i> , 2019, 9, 13783.	1.6	41
44	Riboflavin Is a Determinant of Total Homocysteine Plasma Concentrations in End-Stage Renal Disease Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1331-1337.	3.0	40
45	Cinacalcet Increases Calcium Excretion in Hypercalcemic Hyperparathyroidism After Kidney Transplantation. <i>Transplantation</i> , 2008, 86, 919-924.	0.5	40
46	Randomized, Single Blind, Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Renal Transplant Recipients. <i>PLoS ONE</i> , 2012, 7, e46133.	1.1	40
47	Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 37, 758-765.	2.1	39
48	A critical appraisal for definition of hyperfiltration. <i>American Journal of Kidney Diseases</i> , 2004, 43, 396.	2.1	39
49	Genetic determinants of the homocysteine level. <i>Kidney International</i> , 2003, 63, S141-S144.	2.6	38
50	Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. <i>American Journal of Kidney Diseases</i> , 2001, 38, 956-964.	2.1	36
51	Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. <i>Transplant International</i> , 2007, 20, 247-255.	0.8	35
52	Kidney transplantation in patients with Fabry disease. <i>Transplant International</i> , 2009, 22, 475-481.	0.8	35
53	An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 333-337.	1.4	35
54	Molecular Genetics of Homocysteine Metabolism. <i>Mineral and Electrolyte Metabolism</i> , 1999, 25, 269-278.	1.1	34

#	ARTICLE	IF	CITATIONS
55	Effect of Glutamate Carboxypeptidase II and Reduced Folate Carrier Polymorphisms on Folate and Total Homocysteine Concentrations in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1314-1319.	3.0	34
56	Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. <i>Atherosclerosis</i> , 2004, 174, 43-48.	0.4	34
57	Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1832-1838.	3.0	34
58	Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial. <i>BMC Nephrology</i> , 2017, 18, 238.	0.8	33
59	Evidence for an Increased Generation of Prostacyclin in the Microvasculature and an Impairment of the Platelet α -Granule Release in Chronic Renal Failure. <i>Thrombosis and Haemostasis</i> , 1988, 60, 205-208.	1.8	33
60	Dialysate Sodium Prescription and Blood Pressure in Hemodialysis Patients. <i>American Journal of Hypertension</i> , 2014, 27, 1160-1169.	1.0	32
61	Safety Aspects of Parenteral Iron in Patients with End-Stage Renal Disease. <i>Drug Safety</i> , 1997, 17, 241-250.	1.4	31
62	The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. <i>European Journal of Echocardiography</i> , 2011, 12, 744-749.	2.3	31
63	Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. <i>Transplant International</i> , 2009, 22, 287-292.	0.8	30
64	Dialysis and Transplantation in Fabry Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 379-385.	2.2	30
65	Anti-interleukin-1 α autoantibodies in hemodialysis patients. <i>Kidney International</i> , 1991, 40, 787-791.	2.6	29
66	Angiotensin converting enzyme DD genotype is associated with hypertensive crisis*. <i>Critical Care Medicine</i> , 2002, 30, 2236-2241.	0.4	29
67	Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). <i>Trials</i> , 2013, 14, 196.	0.7	29
68	Malposition of a Dialysis Catheter in the Accessory Hemiazygos Vein. <i>Anesthesia and Analgesia</i> , 1996, 83, 883-885.	1.1	28
69	Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 1098-1103.	2.1	28
70	Potential risk for infection and atherosclerosis due to iron therapy. , 2005, 15, 105-110.		28
71	Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. <i>Blood</i> , 2001, 97, 2914-2915.	0.6	27
72	Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 38, 77-84.	2.1	27

#	ARTICLE	IF	CITATIONS
73	Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. <i>Kidney International</i> , 2003, 64, 1095-1100.	2.6	27
74	Endothelial Progenitor Cells in Kidney Transplant Recipients. <i>Transplantation</i> , 2006, 81, 599-606.	0.5	27
75	Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. <i>Kidney International</i> , 1999, 55, 2054-2061.	2.6	26
76	Effect of erythropoietin on cardiovascular diseases. <i>American Journal of Kidney Diseases</i> , 2001, 38, S20-S25.	2.1	26
77	Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 334-338.	1.0	26
78	Anemia is a new complication in Fabry disease: Data from the Fabry Outcome Survey. <i>Kidney International</i> , 2005, 67, 1955-1960.	2.6	24
79	History of Cardiovascular Disease Is Associated With Endothelial Progenitor Cells in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 46, 520-528.	2.1	24
80	Reversibility of 'Secondary Hypercalcitoninemia' After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1757-1763.	2.6	24
81	Results of an Ophthalmologic Screening Programme for Identification of Cases with Anderson-Fabry Disease. <i>Ophthalmologica</i> , 2004, 218, 207-209.	1.0	23
82	Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. <i>Kidney International</i> , 2005, 68, 2814-2822.	2.6	23
83	Safe and Efficient Emergency Transvenous Ventricular Pacing via the Right Supraclavicular Route. <i>Anesthesia and Analgesia</i> , 2000, 90, 784-789.	1.1	22
84	Effect of Hemodialysis Before Transplant Surgery on Renal Allograft Function—A Pair of Randomized Controlled Trials. <i>Transplantation</i> , 2009, 88, 1377-1385.	0.5	21
85	Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. <i>Transplant International</i> , 2012, 25, 680-686.	0.8	21
86	Employment Status and Associations with Workability, Quality of Life and Mental Health after Kidney Transplantation in Austria. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1254.	1.2	21
87	G-Protein β_3 subunit gene (GNB3) polymorphism 825C>T in patients with hypertensive crisis. <i>Critical Care Medicine</i> , 2000, 28, 3203-3206.	0.4	20
88	Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B12 in kidney transplant recipients. <i>Kidney International</i> , 2005, 67, 1980-1985.	2.6	20
89	Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta. <i>Molecular Genetics and Metabolism</i> , 2008, 95, 114-115.	0.5	20
90	Clinical evaluation of two novel bioactive PTH(1-84) assays in hemodialysis patients. <i>Clinical Biochemistry</i> , 2012, 45, 1645-1651.	0.8	20

#	ARTICLE	IF	CITATIONS
91	GBV-C/HCV in hemodialysis patients: Anti-E2 antibodies and GBV-C/HCV-RNA in serum and peripheral blood: mononuclear cells. <i>Kidney International</i> , 1998, 53, 212-216.	2.6	18
92	Renal function in heart failure: a disparity between estimating function and predicting mortality risk. <i>European Journal of Heart Failure</i> , 2013, 15, 763-770.	2.9	18
93	Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study. <i>American Journal of Kidney Diseases</i> , 2011, 57, 673-681.	2.1	17
94	A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. <i>Transplant International</i> , 2007, 20, 505-511.	0.8	16
95	Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 79.	0.7	15
96	Upregulation of a lymphoid serine protease in kidney allograft recipients. <i>Kidney International</i> , 1990, 37, 1350-1356.	2.6	14
97	Comparative Look at Intravenous Iron Agents: Pharmacology, Efficacy, and Safety of Iron Dextran, Iron Saccharate, and Ferric Gluconate. <i>Seminars in Dialysis</i> , 1999, 12, 243-248.	0.7	14
98	Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity in Patients with Chronic Kidney Disease and Chronic Metabolic Acidosis. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 188-199.	0.9	14
99	Functional characterization of cytokine autoantibodies in chronic renal failure patients. <i>Kidney International</i> , 1994, 45, 1484-1488.	2.6	13
100	Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 519.	1.8	13
101	Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1069-1073.	0.7	13
102	Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease. <i>Current Hypertension Reviews</i> , 2015, 10, 112-120.	0.5	13
103	Two novel mutations in the $\hat{1}^2$ subunit of the human epithelial sodium channel. <i>Kidney International</i> , 1999, 55, 2530-2531.	2.6	12
104	Effects of TCN2 776C>G on vitamin B12, folate, and total homocysteine levels in kidney transplant patients. <i>Kidney International</i> , 2004, 65, 1877-1881.	2.6	12
105	Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. <i>Kidney International</i> , 2004, 66, 295-302.	2.6	12
106	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. <i>Frontiers in Immunology</i> , 2021, 12, 720183.	2.2	12
107	Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. <i>Kidney International</i> , 2001, 59, 253-257.	2.6	12
108	Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. <i>Journal of Nephrology</i> , 2013, 26, 645-651.	0.9	12

#	ARTICLE	IF	CITATIONS
109	Patterns of co-occurrence of three single nucleotide polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene in kidney transplant recipients. <i>European Journal of Clinical Investigation</i> , 2004, 34, 613-618.	1.7	11
110	Parathyroid Hormone Secretion During Citrate Anticoagulated Hemodialysis in Acutely Ill Maintenance Hemodialysis Patients. <i>Anesthesia and Analgesia</i> , 2004, 99, 1199-1204.	1.1	11
111	Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. <i>Kidney International</i> , 2005, 68, 2857-2862.	2.6	11
112	Prognostic Associations Between Lipid Markers and Outcomes in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 509-517.	2.1	11
113	Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis. <i>Kidney International</i> , 2010, 77, S8-S11.	2.6	11
114	A SAGE based approach to human glomerular endothelium: defining the transcriptome, finding a novel molecule and highlighting endothelial diversity. <i>BMC Genomics</i> , 2014, 15, 725.	1.2	11
115	A pharmacological chaperone on the horizon. <i>Nature Reviews Nephrology</i> , 2016, 12, 653-654.	4.1	11
116	Hyperhomocysteinemia in organ transplantation. <i>Current Opinion in Urology</i> , 2000, 10, 87-94.	0.9	10
117	Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. <i>Kidney International</i> , 2001, 59, S253-S257.	2.6	10
118	Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. <i>Kidney International</i> , 2002, 61, 1894-1898.	2.6	10
119	Impact of Measures to Enhance the Value of Observational Surveys in Rare Diseases: The Fabry Outcome Survey (FOS). <i>Value in Health</i> , 2011, 14, 862-866.	0.1	10
120	C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 247.	1.2	10
121	Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 566-569.	1.0	9
122	Morbus Fabry in Österreich. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 235-240.	1.0	9
123	Iron overload in kidney transplants: Prospective analysis of biochemical and genetic markers. <i>Kidney International</i> , 2005, 67, 691-697.	2.6	9
124	Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2015, 28, 679-689.	0.9	9
125	Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency. <i>Journal of the Neurological Sciences</i> , 2017, 383, 123-127.	0.3	9
126	Migalastat for the treatment of Fabry disease. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 301-309.	0.5	9

#	ARTICLE	IF	CITATIONS
127	Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 225-234.	1.4	9
128	The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2640.	1.0	9
129	Quantification of Î±-galactosidase activity in intact leukocytes. <i>Clinica Chimica Acta</i> , 2010, 411, 1666-1670.	0.5	8
130	Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy. <i>International Journal of Medical Sciences</i> , 2016, 13, 340-346.	1.1	8
131	Molecular Analysis of the Carboxy Terminus of the Beta and Gamma Subunits of the Epithelial Sodium Channel in Patients with End-Stage Renal Disease. <i>Nephron</i> , 1999, 81, 381-386.	0.9	7
132	Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells?. <i>Kidney International</i> , 2001, 59, S258-S261.	2.6	7
133	Genetic Aspects of Hyperhomocysteinemia in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2006, 26, 8-13.	0.6	7
134	Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. <i>Clinical Biochemistry</i> , 2014, 47, 1316-1319.	0.8	7
135	Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 182.	0.7	7
136	Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. <i>European Journal of Internal Medicine</i> , 2020, 73, 51-58.	1.0	7
137	Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy. <i>Kidney Medicine</i> , 2020, 2, 213-217.	1.0	7
138	100 years of inherited metabolic disorders in Austria – A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. <i>Journal of Inherited Metabolic Disease</i> , 2022, 45, 144-156.	1.7	7
139	Percutaneous Nonangiographic Insertion of Hickman Catheters in Marrow Transplant Recipients by Anesthesiologists and Intensivists. <i>Anesthesia and Analgesia</i> , 1997, 84, 80-84.	1.1	6
140	Radiological Screening for Hickman Catheter Insertion. <i>Anesthesia and Analgesia</i> , 1998, 86, 216-217.	1.1	6
141	Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis. <i>Transplant Immunology</i> , 2008, 20, 14-20.	0.6	6
142	Effect of Conversion From Cyclosporin to Tacrolimus on Endothelial Progenitor Cells in Stable Long-Term Kidney Transplant Recipients. <i>Transplantation</i> , 2013, 95, 1338-1345.	0.5	6
143	Exclusion of pregnancy in dialysis patients: diagnostic performance of human chorionic gonadotropin. <i>BMC Nephrology</i> , 2020, 21, 70.	0.8	6
144	Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomains – Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. <i>Covid</i> , 2021, 1, 105-114.	0.7	6

#	ARTICLE	IF	CITATIONS
145	Central Venous Catheterization in a Patient in the Prone Position. <i>Critical Care Medicine</i> , 1997, 25, 1439-1440.	0.4	6
146	First case of atypical haemolytic uremic syndrome following Covid-19 vaccination with BNT162b2. <i>Clinical Kidney Journal</i> , 0, , .	1.4	6
147	Pathophysiology and Clinical Importance of Hyperhomocysteinemia: Clinical Intervention Studies. <i>Mineral and Electrolyte Metabolism</i> , 1999, 25, 286-290.	1.1	5
148	Iron Therapy in Renal Transplant Recipients. <i>Transplantation</i> , 2004, 78, 1239-1240.	0.5	5
149	Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 964.	1.0	5
150	COVID-19 serology in nephrology healthcare workers. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 923-930.	1.0	5
151	A Coincidence of Disastrous Accidents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 43, 556-557.	1.1	5
152	TGF-beta1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. <i>Transplant International</i> , 2003, 16, 843-848.	0.8	4
153	Cardiovascular Disease Mortality in Kidney Transplant Recipients: No Light at the End of the Tunnel?. <i>American Journal of Kidney Diseases</i> , 2012, 59, 754-757.	2.1	4
154	Agreement of dried blood spot lyso-Gb3 concentrations obtained from different laboratories in patients with Fabry disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e275-e278.	1.4	4
155	Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron. <i>Viruses</i> , 2022, 14, 1181.	1.5	4
156	Exercise Chronotropy in Patients with Normal and Impaired Sinus Node Function After Cardiac Transplantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 1793-1799.	0.5	3
157	Approaching the End of the Homocysteine Hype?. <i>American Journal of Kidney Diseases</i> , 2008, 51, 549-553.	2.1	3
158	Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort. <i>Journal of Nephrology</i> , 2022, 35, 451-461.	0.9	3
159	MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease. <i>Genes</i> , 2021, 12, 1184.	1.0	3
160	Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0135674.	1.1	3
161	The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. <i>Clinical Laboratory</i> , 2016, 62, 1965-1972.	0.2	3
162	Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1087-1093.	1.7	2

#	ARTICLE	IF	CITATIONS
163	SP730PREEMPTIVE PLASMA THERAPY AND ECULIZUMAB RESCUE FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME RELAPSE FOLLOWING KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i592-i593.	0.4	2
164	A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. <i>PLoS ONE</i> , 2019, 14, e0218709.	1.1	2
165	Pregnancies in kidney transplant recipients with complement gene variant-mediated thrombotic microangiopathy. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1255-1260.	1.4	2
166	Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, CJN.03850321.	2.2	2
167	Can Hemodialysis Technique Modify the Hypercatabolic State?. <i>Renal Failure</i> , 1996, 18, 395-404.	0.8	1
168	Underuse of Hardy-Weinberg equilibrium. <i>Kidney International</i> , 2004, 66, 1711.	2.6	1
169	No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2007, 27, 390-396.	1.4	1
170	Fabry Disease. , 2014, , 381-387.		1
171	FO021ORAL SODIUM BICARBONATE SUPPLEMENTATION DOES NOT AFFECT SERUM CALCIFICATION PROPENSITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND CHRONIC METABOLIC ACIDOSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i9-i10.	0.4	1
172	SP046EFFECT OF SODIUM BICARBONATE LOAD ON 24-HOUR AMBULATORY BLOOD PRESSURE MEASUREMENTS IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE: PRELIMINARY RESULTS OF THE SOBIC STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	1
173	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S53.	0.5	1
174	Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis. <i>Frontiers in Medicine</i> , 2021, 8, 711034.	1.2	1
175	Fabry Disease Case Finding Studies in High-Risk Populations. , 2010, , 153-162.		1
176	Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 37.	1.2	1
177	Permanent Catheters Damaged by Power Injection of Contrast Media. <i>Journal of Parenteral and Enteral Nutrition</i> , 1995, 19, 428-428.	1.3	0
178	TGF- β 1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. <i>Transplant International</i> , 2002, 16, 843-848.	0.8	0
179	Automated Fluorescence Polarization Immunoassay for Measurement of Increased Total Homocysteine Plasma Concentrations in Hemodialysis Patients. <i>Laboratory Medicine</i> , 2003, 34, 538-542.	0.8	0
180	Therapy of Fabry disease. <i>Kidney International</i> , 2004, 66, 1288.	2.6	0

#	ARTICLE	IF	CITATIONS
181	Response of patients with Fabry disease with the amenable GLA mutation p.N215S to treatment with migalastat. <i>Molecular Genetics and Metabolism</i> , 2017, 120, S68-S69.	0.5	0
182	Relationship between CFHR5 and complement parameters in patients suffering from complement-mediated kidney disorders, with or without CFHR5 mutations. <i>Molecular Immunology</i> , 2017, 89, 177.	1.0	0
183	FP714LONG-TERM NEURODEVELOPMENTAL AND ANTHROPOMETRICAL OUTCOME OF CHILDREN BORN TO FEMALE KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i286-i286.	0.4	0
184	SP007EARLY FETAL OUTCOME OF 28 PREGNANCIES IN WOMEN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i348-i349.	0.4	0
185	Assessment of the C3b- and iC3b-binding ability of CFHR5 variants. <i>Molecular Immunology</i> , 2018, 102, 141.	1.0	0
186	First case of late onset cardiac phenotype Fabry disease due to an AluYb8 insertion in exon 7 of the GLA gene. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1182-1182.	0.5	0
187	Design of a prospective, multicenter, multinational, observational safety and outcomes registry in Fabry disease patients treated with migalastat and untreated patients. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S140-S141.	0.5	0
188	Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S141.	0.5	0
189	Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-7.	0.2	0
190	P0179ECULIZUMAB USE IN A TERTIARY CARE NEPHROLOGY CENTER. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
191	Homocysteine and atherosclerosis in dialysis patients. , 2004, , 809-827.		0